Lexology December 9, 2024
By Stephen Forster, Alexander Hastings and Howard Young (December 9, 2024, 6:52 PM EST)
Shortly after the new year, a Trump-Vance administration will control the White House, and the Republicans will hold a narrow majority in both the U.S. House of Representatives and U.S. Senate.
This control trifecta is likely to affect both legislative and regulatory processes and provide pathways for potential changes to the drug pricing and reimbursement landscapes.
While President-elect Donald Trump has yet to articulate priorities with respect to drug pricing and reimbursement, his reform efforts during his prior administration and the ongoing bipartisan focus on drug affordability suggest that drug pricing will continue to be under scrutiny.
Stephen Forster
We discuss herein key drug pricing programs...
Today's Sponsors
Today's Sponsor